N-nitrosation of N-methylaniline and nitrosamine toxicology in the wistar rats

The aim of this study is to investigate the urinary excretion of nitrosamine ions in rats, to investigate the effect of precursors of N-nitrosamine on serum enzymes activities and to evaluate the toxicity on liver on exposure to N- nitrosamine precursors. Forty two male wistar rats were divided into six groups and each group was admininistered with varying doses of sodium nitrite and N-methylaniline. The following methods were used; spectrophotometry, thin layer chromatography, cell fractionation, centrifugation, dialysis, histopathology, enzymatic and colorimetry. The RF values of the test samples were similar to those of the test standard, signifying the presence of N-nitrosamine in the urine of the rat. Liver function test, showed significant elevations (P < 0.05) in the AST, ALT, ALP and GGT activities in all the test groups compared with the control. Histological evaluation showed severe haemorrhage within the sinusoid, the portal triad was infiltrated by inflammatory cells in both NaNO2 induced group and NMA combined with NaNO2 group, thus showing acute damage compared with the control group which showed no lesion. The present study showed the urinary excretion of nitrosamine formed from N-methylaniline and sodium nitrite, the effect of N-methylaniline and sodium nitrite on serum enzymes and their toxicity on the liver of wistar rats

Sub-Cellular Correlation of Nitrite in Cassava (Manihot Esculenta Crantz) Leaves and Nitrosamine Toxicology in Wistar Rats

The aim of this study was to determine the nitrite levels in the sub-cellular fractions of cassava (Manihot esculenta crantz) leaves containing chloroplast, mitochondria and in the cytosol respectively and to their contribution in the causation of liver toxicity in rats exposed to N-nitrosamine precursors. The design of this experiment consisted of three animal groups. The first group was administered with dimethylamine hydrochloride plus sodium nitrite (DMA.HCL + NaNO2), the second group was administered with sodium nitrite (NaNO2) only and the third group (control) was given distilled water. The methods used included cell fractionation, tissue homogenization and centrifugation, spectrophotometric analysis, enzymatic determination and histopathology. Nitrite levels were estimated at 6.08 ± 0.92, 4.06 ± 1.65 and 1.29 ± 1.66μg/200g of cassava leaf tissue in chloroplasmic, mitochondrial and cytosolic sub-cellular fractions respectively. Both the NaNO2 dose regime and the combined dose of DMA.HCL and NaNO2, at P- value 0.05, caused significant increases in GGT, ALP, AST and ALT levels in serum. The histopathological study of the rat liver for DMA.HCL + NaNO2 administration showed severe portal and central venous congestion while the NaNO2 administration revealed a mild periportal cellular infiltration. This study shows that there is a correlation of nitrite in the chloroplast, mitochondria and cytosol sub-cellular fractions of cassava leaves and administration of nitrite dietary level in cassava leaves and dimethylamine hydrochloride produced acute synergistic toxicity in the liver

Metabolism of precursors of N-nitrosamine in vitro and nitrosamine toxicology in wistar rat

The aim of this study was to determine the level of nitrite in post mitochondrial fraction of liver and the toxicity in liver and kidney of wistar rat. Forty two male wistar rats were divided into six groups and each group was with varying doses of sodium nitrite and N-methylaniline. The following methods were employed, spectrophotometric, cell fractionation, centrifugation, dialysis, histopathology and ultra violet irradiation. There was a significant increase (P < 0.05) in the level of nitrite in the post mitochondrial fraction of liver in all the experimental groups compared to the control. After exposure to UV-light there was a decrease in the level of nitrite in all the groups, which indicates that the UV-light has degraded the precursors of N-nitrosamine. The histopathology study showed severe haemorrhage within sinusoid, the portal triad was infiltrated by inflammatory cells within the sinusoid of the liver and kidney. The present study showed that the concentration of nitrite in the post mitochondrial fraction of the liver of the rat depends on the dose of the toxins. The study also showed UV degradation of precursors of Nnitrosamine and the effect of the toxins on both liver and kidney

N-Nitrosation of dimethylamine hydrochloride and its toxicology in the wistar rats fed different levels of dietary protein

The present study investigated the in vivo and in vitro effects of orally administered sodium nitrite (NaNO2) and dimethylamine hydrochloride (DMA–HCL) on liver of rats fed ad libitum with high protein diet (64%), normal protein diet (27%) and low protein diet (3.5%). Thirty Male Wistar rats were divided into three groups and kept for four weeks. Group one was given high protein diet, group two was given a normal protein diet, group three was given low protein diet, all the groups were administered with 3mg NaNO2 and 20mg DMA-HCL/kg, using the application of spectrophotometric analysis, centrifugation, histolopathology, enzymatic as well as colorimetric methods. Liver function test, showed significant elevations (P < 0.05) in the AST, ALT, ALP and GGT activities in all the groups compared with the control animals. The histopathology examination exhibited periportal necrosis. Following UV exposure after in vitro incubation of rat liver microsomal plus soluble fraction with NaNO2 plus DMA-HCL, nitrite concentration in the rats fed high protein was highest 4.033 and 0.470 μg/ml, compared to the control rats which was 0.052 and 0.00192 μg/ml before and after UV irradiation. Nitrite loss was significant (p<0.05) before and after UV exposure in all the groups, indicating that the UV-light has degraded the nitrosamine precursors, thereby inhibiting possible nitrosation. The study has revealed that in rats, a high protein diet enhances N-Nitrosation of dimethylamine hydrochloride, liver derangement and the metabolisms in vivo and in vitro of the resultant compound

Demulsification of Crude Oil Emulsion in Well X in a Niger Delta Field

Crude oil emulsion is an inevitable phenomenon in hydrocarbon production. Treatment of crude oil emulsion is challenging when the emulsion is stabilized. As crude oil is brought to the surface and pumped to the production facilities, the formation of emulsion increases operating cost. There is a wide array of demulsifiers that are available in the oil and gas industry for the treatment of crude oil emulsion, but one major concern has always been the efficiency of the treatment. No single universal demulsifier can effectively remove emulsion and a combination of two or more is usually expensive. In this study, crude samples were collected from the inlet manifold of a Niger Delta field and bottle tests were conducted with several demulsifiers to select the best chemical demulsifier for use in treating the emulsions as well as the optimum combination. To achieve this objective, twelve different industrial-based demulsifiers were considered which were EXP50, Separol NF-36, Baker-Basf V13-312, Servo CC-8271, Tretolite RP6275, NACCO-Exxon 006-1442, DMO87005, EXP30, AnticorQIT007, AnticorBE027, DMO86634 and DMO81656. It was observed that DMO87005 and AnticorQIT007 produced better results based on separated water volume than other demulsifiers. Hence, the decision to use these demulsifiers to assess their combined potential and the demulsifier factors, namely, concentration, temperature and time effects on the separated water volume using design of experiments (DOE) approach. The results obtained shows that the selected demulsifiers DMO87005 and AnticorQIT007 in a combined form separate more water volume from the crude oil emulsion. Also, the performance of the combined demulsifier is dependent on the combination ratio of the selected demulsifiers. Furthermore, the results depict that the selected (non-combined) demulsifiers and the combined demulsifier factors’ main effects on the separated water volume are concentration, while concentration-time and temperature-time are the factors’ interaction effects for selected and combined demulsifiers, respectively. Again, the magnitude of the main and interaction effects of the combined demulsifier’s factors on the separated water volume is affected by the selected demulsifiers combination ratio. Thus, the combined demulsifier at 0.45mL concentration at a temperature of 90°C for 60 minutes gave a good potential that would necessitate its use for crude oil emulsion treatment in the Niger Delta

Endoparasites of Bucks Raised under Intensive and Semi-Intensive System

An investigation was carried out on bucks in intensive and semi-intensive systems of management. A total of sixteen (16) bucks (male goats) were randomly purchased for the study. The animals were divided into four groups of four animals per treatment and fed Panicum maximum, Gliricidia sepium for Treatment 1 while Treatment 2 were fed Panicum maximum, Gliricidia sepium plus concentrates. Those in T3 were fed concentrate and allowed to graze and T4 were fed Panicum maximum and were also allowed to forage. The result showed significant difference (P&lt;0.05) in infestations of strongyles amongst the treatments

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

OBJECTIVE: We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). METHODS: We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. RESULTS: We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). CONCLUSION: Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases : Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Funding Information: Competing interests SES has received funding from the Vasculitis Foundation and the Vasculitis Clinical Research Consortium unrelated to this work. JL has received research grant funding from Pfizer unrelated to this work. ES is a Board Member of the Canadian Arthritis Patient Alliance, a patient run, volunteer-based organisation whose activities are primarily supported by independent grants from pharmaceutical companies. MP was supported by a Rheumatology Research Foundation Scientist Development grant. DA-R is a Scientific Advisor for GlaxoSmithKilne unrelated to this work. FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma outside of the submitted work. No funding relevant to this manuscript. RC: speakers bureau for Janssen, Roche, Sanofi, AbbVie. KD reports no COI-unpaid volunteer president of the Autoinflammatory Alliance. Any grants or funding from pharma is received by the non-profit organisation only. CLH received funding under a sponsored research agreement unrelated to the data in the paper from Vifor Pharmaceuticals. LeK has received a research grant from Lilly unrelated to this work. AHJK participated in consulting, advisory board or speaker's bureau for Alexion Pharmaceuticals, Aurinia Pharmaceuticals, Annexon Biosciences, Exagen Diagnostics and GlaxoSmithKilne and received funding under a sponsored research agreement unrelated to the data in the paper from GlaxoSmithKline. JSingh has received consultant fees from Crealta/ Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD and Practice Point Communications; and the National Institutes of Health and the American College of Rheumatology. JSingh owns stock options in TPT Global Tech, Vaxart Pharmaceuticals and Charlotte’s Web Holdings. JSingh previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals. JSingh is on the speaker’s bureau of Simply Speaking. JSingh is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organisation that develops outcome measures in rheumatology and receives arms-length funding from eight companies. JSingh serves on the FDA Arthritis Advisory Committee. JSingh is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. JSingh is the editor and the Director of the University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. NSingh is supported by funding from the Rheumatology Research Foundation Investigator Award and the American Heart Association. MFU-G has received research support from Pfizer and Janssen, unrelated to this work. SB reports personal fees from Novartis, AbbVie, Pfizer and Horizon Pharma, outside the submitted work. RG reports personal fees from AbbVie New Zealand, Cornerstones, Janssen New Zealand and personal fees and non-financial support Pfizer New Zealand (all <US$10 000) outside the submitted work. PMM reports personal fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB, grants and personal fees from Orphazyme, outside the submitted work. PCR reports personal fees from AbbVie, Gilead, Lilly and Roche, grants and personal fees from Novartis, UCB Pharma, Janssen and Pfizer and non-financial support from BMS, outside the submitted work. PS reports honoraria from Social media editor for @ACR_Journals, outside the submitted work. ZSW reports grants from NIH, BMS and Principia/ Sanofi and personal fees from Viela Bio and MedPace, outside the submitted work. JY reports personal fees from Pfizer and Eli Lilly, and grants and personal fees from AstraZeneca, outside the submitted work. MJL reports grants from American College of Rheumatology, during the conduct of the study and consulting fees from AbbVie, Amgen, Actelion, Boehringer Ingelheim, BMS, Celgene, Gilead, J&J, Mallinckrodt, Novartis, Pfizer, Roche, Sandoz, Sanofi, Sobi and UCB, outside the submitted work. LGR was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences (NIEHS; ZIAES101074) of the National Institutes of Health. JH reports grants from Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Rheumatology Research Alliance, and personal fees from Novartis, Pfizer and Biogen, outside the submitted work. JSimard received research grant funding from the National Institutes of Health unrelated to this work (NIAMS: R01 AR077103 and NIAID R01 AI154533). JSparks has performed consultancy for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Inova Diagnostics, Optum and Pfizer unrelated to this work. Funding Information: Funding This study was supported by the European Alliance of Associations for Rheumatology and American College of Rheumatology Research and Education Foundation. Dr. Lisa Rider's involvement was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences. Publisher Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Background. We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. Results We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. Conclusion. Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.publishersversionPeer reviewe